COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

(2021) Moriah Bergwerk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

(2021) Anat Achiron et al.   European Journal of Internal Medicine

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

(2021) Anat Achiron et al.   JOURNAL OF NEUROIMMUNOLOGY

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE